These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14988769)

  • 1. Clinical use of sibutramine.
    Ryan DH
    Drugs Today (Barc); 2004 Jan; 40(1):41-54. PubMed ID: 14988769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibutramine produces dose-related weight loss.
    Bray GA; Blackburn GL; Ferguson JM; Greenway FL; Jain AK; Mendel CM; Mendels J; Ryan DH; Schwartz SL; Scheinbaum ML; Seaton TB
    Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
    Seagle HM; Bessesen DH; Hill JO
    Obes Res; 1998 Mar; 6(2):115-21. PubMed ID: 9545017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
    Nisoli E; Carruba MO
    Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
    Luque CA; Rey JA
    Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
    Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
    Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.